|
Match
|
Document |
Document Title |
|
|
US20050148512 |
Medical implants and fibrosis-inducing agents
Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between... |
|
|
US20160158264 |
PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using... |
|
|
US20160038525 |
PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients... |
|
|
US20150111839 |
METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS
Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside... |
|
|
US20140371162 |
COMBINATION THERAPY COMPRISING SGLT INHIBITORS AND DPP4 INHIBITORS
The present invention relates to combination therapy comprising a DPP4 inhibitor and an SGLT inhibitor. The combination of the present invention leads to increase plasma GLP-1 level and the... |
|
|
US20140315832 |
PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients... |
|
|
US20140303098 |
PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal... |
|
|
US20140200188 |
2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT
Provided are methods for treating Orthomyxoviridue virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein R2 is halogen. The compounds,... |
|
|
US20140031301 |
PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using... |
|
|
US20120196812 |
PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using... |
|
|
US20120177752 |
NUTRITIONAL COMPOSITIONS INCLUDING BETA-HYDROXY-BETA-METHYLBUTYRATE
The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients... |
|
|
US20110014284 |
PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF
The present invention relates to pharmaceutical compositions comprising a SGLT-2 inhibitor, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders. |
|
|
US20100209506 |
PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF
The present invention relates to pharmaceutical compositions of linagliptin, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders. |
|
|
US20100166735 |
METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS
The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some... |
|
|
US20100159004 |
METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS
The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some... |
|
|
US20100158895 |
METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS
The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some... |
|
|
US20070286876 |
Skin care compositions comprising low concentrations of skin treatment agents
Skin care compositions may comprise from about 0.001% to about 0.1% by weight of hexamidine and either or both of (i) from about 0.001% to about 10% by weight of zinc oxide, and/or (ii) from about... |
|
|
US20070027085 |
Microencapsulation and sustained release of biologically active polypeptides
This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically... |
|
|
US20070021357 |
Treatment of inflammatory conditions
The invention relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin thereby treating or prevention various diseases, disorders or... |
|
|
US20060159736 |
Liposome formulations of boronic acid compounds
A liposome composition comprised of liposomes having the peptide boronic acid proteasome inhibitor compound bortezomib entrapped in the liposomes is described. The boronic acid compound is... |
|
|
US20060111307 |
Methods and compositions for treating pain
Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux... |
|
|
US20050282742 |
Formulation of boronic acid compounds
The invention relates to the formulation of pharmaceutical compounds. More particularly, the invention provides stable, pharmaceutically acceptable compositions prepared from boronic acid... |
|
|
US20050267047 |
Diarylalkanes as potent inhibitors of binuclear enzymes
The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular... |
|
|
US20170020907 |
PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using... |
|
|
US20150148305 |
COMPOSITION AND METHOD FOR COMPOUNDED THERAPY
The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The... |
|
|
US20140274921 |
GLYCOSIDE DERIVATIVES AND USES THEREOF
This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium... |
|
|
US20130137646 |
METHODS OF TREATMENT, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising... |
|
|
US20120244222 |
OSMOTIC MEDIATED RELEASE SYNTHETIC NANOCARRIERS
This invention relates, at least in part, to osmotic mediated release barrier-free synthetic nanocarriers and methods of production and use. |
|
|
US20120177744 |
METHOD OF USING BETA-HYDROXY-BETA-METHYLBUTYRATE FOR THE TREATMENT OF CANCER
Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the... |
|
|
US20110150778 |
Assembly of Gas-Filled Microvesicle With Active Component For Contrast Imaging
Assembly comprising a gas-filled microvesicle and a structural entity which is capable to associate through an electrostatic interaction to the outer surface of said microvesicle (microvesicle... |
|
|
US20110135713 |
Antimicrobial and Antiviral Compounds and Methods for Their Use
The present invention provides protonated compounds having antiviral and antimicrobial activity. The invention also provides antimicrobial compositions comprising protonated compounds of the... |
|
|
US20110046087 |
PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using... |
|
|
US20110046076 |
PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or... |
|
|
US20100255081 |
Method for treating symptoms of diabetes
The present invention provides a method for treating symptoms of diabetes in a diabetic subject which comprises administering to the subject a therapeutically effective amount of an agent which... |
|
|
US20090252785 |
ENDOPLASMIC RETICULUM TARGETING LIPOSOMES
Provided are compositions that include lipid particles, such as liposomes, that can fuse with the ER membrane of a cell. The lipid particles can also deliver a cargo, such as a therapeutic or an... |
|
|
US20090137461 |
ABUSE-RESISTANT AMPHETAMINE PRODRUGS
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for... |
|
|
US20080260680 |
Method of Attenuating Reactions to Skin Irritants
The present invention is directed to a method of inhibiting CDld activation by administering a composition containing a moiety that blocks CDld activation. Compositions of the invention are useful... |
|
|
US20080008764 |
CARBON-SUBSTITUTED DIKETOPIPERAZINE DELIVERY SYSTEMS
Compositions useful in the delivery of active agents are provided. These delivery compositions include (a) an active agent; and (b) a carrier of at least one mono-C-substituted or di-C-substituted... |
|
|
US20070196445 |
Method for the Prevention and Treatment of Cachexia and Anorexia
The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition... |
|
|
US20070099848 |
Rapamycin carbohydrate derivatives
This invention provides modified rapamycins that have specific monosaccharide(s), oligosaccharide(s), pseudosugar(s) or derivatives thereof attached through a linker to create rapamycin... |
|
|
US20060276412 |
METHODS AND COMPOSITIONS FOR MANAGING PSYCHOTIC DISORDERS
Compositions for treating psychotic disorders comprise a first ingredient and a second ingredient, wherein the first ingredient comprises at least one antipsychotic agent selected from the group... |
|
|
US20050277579 |
Compositions for affecting weight loss
Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an antidiabetic and the second compound is a anticonvulsant.... |
|
|
US20050232989 |
Process for preparing oral calcium compositions
A process for the preparation of an orally administrable calcium composition comprising the steps of: (i) obtaining a physiologically tolerable particulate calcium compound having a mean particle... |
|
|
US20050232872 |
Compositions and methods for enhancing receptor-mediated cellular internalization
Compositions and methods for improving cellular internalization of one or more compounds are disclosed. The compositions include a compound to be delivered and a biocompatible viscous material,... |
|
|
US20050137143 |
Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
The present invention relates to glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R1 represents a hydrogen atom or a lower alkyl group; one of Q1 and T1 represents... |
|
|
US20050130909 |
Dalbavancin compositions for treatment of bacterial infections
The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of a mixture of dalbavancin multimers and monomers for... |
|
|
US20050090433 |
Dalbavancin compositions for treatment of bacterial infections
The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of a mixture of dalbavancin multimers and monomers for... |
|
|
US20050065097 |
Carotenoid ether analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
A method of treating ischemic reperfusion injury in a subject. The method may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The... |
|
|
US20050043250 |
Cancer treatment including glycolytic inhibitors
Glycolytic inhibitors are useful in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. 2-deoxyglucose, oxamate and various analogs thereof are identified as... |
|
|
US20150376185 |
N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions... |